34 results on '"Meinl, Ingrid"'
Search Results
2. Anti-CD20 therapies and pregnancy in neuroimmunologic disorders: A cohort study from Germany
3. Neurological phenotypes in patients with NLRP3-, MEFV-, and TNFRSF1A low-penetrance variants
4. Prospective validation of the PML risk biomarker L-Selectin and influence of natalizumab extended intervals
5. Ocrelizumab treatment modulates B-cell regulating factors in multiple sclerosis
6. Ocrelizumab Treatment Modulates B-Cell Regulating Factors in Multiple Sclerosis
7. Relapse-independent multiple sclerosis progression under natalizumab
8. Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis
9. Anti-CD20 therapies and pregnancy in neuroimmunologic disorders
10. De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate
11. Natalizumab Use During the Third Trimester of Pregnancy
12. Additional file 1 of Neurological phenotypes in patients with NLRP3-, MEFV-, and TNFRSF1A low-penetrance variants
13. Ocrelizumab Treatment Modulates B-Cell Regulating Factors in Multiple Sclerosis.
14. Rebound of Disease Activity After Withdrawal of Fingolimod (FTY720) Treatment
15. Confirmed Progression independent of Relapse Activity in Multiple Sclerosis Patients under long-term Natalizumab Treatment. (1372)
16. Fingolimod Profoundly Reduces Frequencies and Alters Subset Composition of Circulating T Follicular Helper Cells in Multiple Sclerosis Patients
17. Anti CD20 Therapies and Pregnancy in Neuroimmunological Disorders – A Case Series from Germany (P4.2-094)
18. Early relapse after rituximab initiation in a patient with neuromyelitis optica spectrum disease and side effects to subsequent tozilizumab therapy: need for further treatment options?
19. Long-term exposure to natalizumab during pregnancy – a prospective case series from the German Multiple Sclerosis and Pregnancy Registry (P2.101)
20. Features of Human CD3+CD20+ T Cells
21. Recurrence of disease activity during pregnancy after cessation of fingolimod in multiple sclerosis.
22. Therapie der Multiplen Sklerose mit Natalizumab:Klinische Wirksamkeit und Veränderung der zirkulierenden Immunzellsubtypen bei einem hochaktiven Patientenkollektiv
23. PML risk stratification using anti-JCV antibody index and L-selectin
24. Predictors for multiple sclerosis relapses after switching from natalizumab to fingolimod
25. Risk Factors for Relapses After Switching From Natalizumab To Fingolimod (P7.241)
26. Early Initiation of Fingolimod Treatment Reduces the Recurrence of Disease Activity after Natalizumab Discontinuation in Multiple Sclerosis (P01.199)
27. Natalizumb in Active MS during Pregnancy: Efficacy, Safety, and the Consequences for Foetal Haematopoiesis (P02.125)
28. PML risk stratification using anti-JCV antibody index and L-selectin.
29. Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis
30. L-Selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients.
31. Features of Human CD3+CD20+ T Cells.
32. Ocrelizumab Treatment Modulates B-Cell Regulating Factors in Multiple Sclerosis.
33. PML risk stratification using anti-JCV antibody index and L-selectin.
34. Predictors for multiple sclerosis relapses after switching from natalizumab to fingolimod.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.